Mankind Pharma Approves Unaudited Standalone & Consolidated Results for Quarter Ended Sep 30, 2025
Mankind Pharma board approves unaudited standalone and consolidated financial results for quarter ended September 30, 2025. Meeting held on November 6, 2025.
Approval of quarterly results and auditor review is a routine but important update. Income tax proceedings are noted, but the company believes there will be no material impact.
The announcement primarily concerns the approval of financial results and routine updates, with no indication of significant positive or negative performance.
* The Board of Directors of Mankind Pharma Limited approved the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025, in a meeting held on November 6, 2025, which commenced at 03:00 p.m. (IST) and concluded at 04:00 p.m. (IST). * The results were reviewed by M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., Joint Statutory Auditors. * The company's share of net profit is ₹1.58 crore for 4 partnership firms and ₹4.75 crore for another set of 4 partnership firms for the quarter ended September 30, 2025. * Income tax proceedings initiated against the Company by the Income tax Department are ongoing, with appeals pending with appellate tax authorities. * The Board approved the Scheme of Amalgamation between the Company and its three wholly owned subsidiaries, Shree Jee Laboratory Private Limited, JPR Labs Private Limited and Jaspack Industries Private Limited, with the appointed date being April 01, 2024. * The Board approved the transfer of the Over the Counter ("OTC") Business of the Company to its wholly owned subsidiary company, Mankind Consumer Products Private Limited and the Company has completed the transfer of OTC business undertaking as a going concern on a slump sale basis through a Business Transfer Agreement ("BTA") on September 30, 2024. * During the quarter and six months ended September 30, 2025, the Company has made investments in its subsidiary companies including Lifestar Pharmaceuticals Private Limited, Mankind Life Sciences Private Limited, Mankind Agritech Private Limited, Mankind Medicare Private Limited, Mankind Prime Labs Private Limited. * Subsequent to the quarter end, the Business Undertaking has been transferred effective November 01, 2025.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.